Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

STOK – Stoke Therapeutics, Inc.

Stoke Therapeutics, Inc.
STOK
$11.63
Name : Stoke Therapeutics, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $634,961,984.00
EPSttm : 0.82
finviz dynamic chart for STOK
Stoke Therapeutics, Inc.
$11.63
1.77%
$0.21

Float Short %

26.79

Margin Of Safety %

21

Put/Call OI Ratio

1.85

EPS Next Q Diff

-2.59

EPS Last/This Y

1.73

EPS This/Next Y

-2.93

Price

11.62

Target Price

22.38

Analyst Recom

1.2

Performance Q

56.11

Relative Volume

1.86

Beta

1.14

Ticker: STOK




19 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-06-02STOK9.911.650.221131
2025-06-03STOK10.91.610.071140
2025-06-04STOK10.951.570.221150
2025-06-05STOK10.871.243.001276
2025-06-06STOK11.131.250.001276
2025-06-09STOK11.121.240.451278
2025-06-10STOK11.361.190.151358
2025-06-11STOK11.511.203.251363
2025-06-12STOK11.821.180.331348
2025-06-13STOK11.541.18999.991351
2025-06-16STOK11.741.18999.991351
2025-06-17STOK11.581.200.001361
2025-06-18STOK11.551.170.361374
2025-06-20STOK11.61.130.321417
2025-06-23STOK11.62.060.911016
2025-06-24STOK11.511.970.141023
2025-06-25STOK11.811.850.501045
2025-06-26STOK11.831.853.001047
2025-06-27STOK11.61.850.771050
DateSymbolLastP/C OIP/C VolTotal OI
19 items Current Page1 of 1




19 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-06-02STOK9.91-1.7- 0.14
2025-06-03STOK10.90-1.7- 0.14
2025-06-04STOK10.96-1.7- 0.14
2025-06-05STOK10.88-1.7- 0.14
2025-06-06STOK11.11-1.7- 0.14
2025-06-09STOK11.13-1.7- 0.14
2025-06-10STOK11.35-1.7- 0.14
2025-06-11STOK11.51-1.7- 0.14
2025-06-12STOK11.82-1.7- 0.14
2025-06-13STOK11.54-1.7- 0.14
2025-06-16STOK11.73-7.0- 0.08
2025-06-17STOK11.67-7.0- 0.08
2025-06-18STOK11.57-7.0- 0.08
2025-06-20STOK11.58-7.0- 0.08
2025-06-23STOK11.60-7.0- 0.08
2025-06-24STOK11.50-7.0- 0.08
2025-06-25STOK11.80-7.0- 0.08
2025-06-26STOK11.84-7.0- 0.08
2025-06-27STOK11.62-7.0- 0.08
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
19 items Current Page1 of 1




18 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-06-02STOK-14.6015.7127.67
2025-06-03STOK-14.6015.7127.67
2025-06-04STOK-14.5415.7127.67
2025-06-05STOK-14.5915.7127.67
2025-06-06STOK-29.2115.7127.67
2025-06-09STOK-29.2115.9327.66
2025-06-10STOK-29.2315.9327.66
2025-06-11STOK-29.1115.9328.50
2025-06-12STOK-29.0115.9328.50
2025-06-13STOK-35.0315.9326.61
2025-06-16STOK-35.039.6726.61
2025-06-18STOK-35.039.6726.61
2025-06-20STOK-35.039.6726.61
2025-06-23STOK-35.039.6826.61
2025-06-24STOK-35.039.6826.61
2025-06-25STOK-35.039.6826.61
2025-06-26STOK-35.039.6826.79
2025-06-27STOK-35.039.6826.79
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
18 items Current Page1 of 1

Last Quarter Act. EPS

1.98

Avg. EPS Est. Current Quarter

-0.49

Avg. EPS Est. Next Quarter

-0.61

Insider Transactions

-35.03

Institutional Transactions

9.68

Beta

1.14

Average Sales Estimate Current Quarter

9

Average Sales Estimate Next Quarter

7

Fair Value

14.07

Quality Score

67

Growth Score

30

Sentiment Score

14

Actual DrawDown %

83.8

Max Drawdown 5-Year %

-95.2

Target Price

22.38

P/E

14.78

Forward P/E

PEG

P/S

3.33

P/B

1.81

P/Free Cash Flow

9.18

EPS

0.79

Average EPS Est. Cur. Y​

0.08

EPS Next Y. (Est.)

-2.85

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

26.33

Relative Volume

1.86

Return on Equity vs Sector %

-9.5

Return on Equity vs Industry %

8.3

EPS 1 7Days Diff

-0.1

EPS 1 30Days Diff

1.42

EBIT Estimation

Stoke Therapeutics, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 128
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy; and Zorevunersen (STK-001), an investigational new medicine for the treatment of Dravet syndrome is being evaluated in phase I/II clinical trials. The company also develops programs focused on various targets, including haploinsufficiency diseases of the central nervous system and eye. It has a license and collaboration with Biogen Inc. for the development and commercialization of zorevunersen medicine for the treatment of Dravet syndrome; and Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of genetic neurodevelopmental diseases. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
stock quote shares STOK – Stoke Therapeutics, Inc. Stock Price stock today
news today STOK – Stoke Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch STOK – Stoke Therapeutics, Inc. yahoo finance google finance
stock history STOK – Stoke Therapeutics, Inc. invest stock market
stock prices STOK premarket after hours
ticker STOK fair value insiders trading